These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 12448002)

  • 1. MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer.
    Janssen JW; Cuny M; Orsetti B; Rodriguez C; Vallés H; Bartram CR; Schuuring E; Theillet C
    Int J Cancer; 2002 Dec; 102(6):608-14. PubMed ID: 12448002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas.
    Janssen JW; Imoto I; Inoue J; Shimada Y; Ueda M; Imamura M; Bartram CR; Inazawa J
    J Hum Genet; 2002; 47(9):460-4. PubMed ID: 12202983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
    Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
    Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review.
    Schuuring E
    Gene; 1995 Jun; 159(1):83-96. PubMed ID: 7607576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
    Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
    J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
    Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G
    Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.
    Rodriguez C; Hughes-Davies L; Vallès H; Orsetti B; Cuny M; Ursule L; Kouzarides T; Theillet C
    Clin Cancer Res; 2004 Sep; 10(17):5785-91. PubMed ID: 15355907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.
    Schuuring E; Verhoeven E; Mooi WJ; Michalides RJ
    Oncogene; 1992 Feb; 7(2):355-61. PubMed ID: 1532244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei.
    Bautista S; Theillet C
    Genes Chromosomes Cancer; 1998 Aug; 22(4):268-77. PubMed ID: 9669664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
    Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
    Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
    Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
    Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
    Janssen JW; Vaandrager JW; Heuser T; Jauch A; Kluin PM; Geelen E; Bergsagel PL; Kuehl WM; Drexler HG; Otsuki T; Bartram CR; Schuuring E
    Blood; 2000 Apr; 95(8):2691-8. PubMed ID: 10753852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
    Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
    Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.
    Akervall JA; Michalides RJ; Mineta H; Balm A; Borg A; Dictor MR; Jin Y; Loftus B; Mertens F; Wennerberg JP
    Cancer; 1997 Jan; 79(2):380-9. PubMed ID: 9010112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 11q13 abnormalities in human breast cancer.
    Fantl V; Smith R; Brookes S; Dickson C; Peters G
    Cancer Surv; 1993; 18():77-94. PubMed ID: 8013002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors.
    Courjal F; Louason G; Speiser P; Katsaros D; Zeillinger R; Theillet C
    Int J Cancer; 1996 Aug; 69(4):247-53. PubMed ID: 8797862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
    Gillett C; Fantl V; Smith R; Fisher C; Bartek J; Dickson C; Barnes D; Peters G
    Cancer Res; 1994 Apr; 54(7):1812-7. PubMed ID: 8137296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.